Biologics in rheumatoid arthritis--recommendations for Swiss practice

Swiss Med Wkly. 2011 May 10:141:w13189. doi: 10.4414/smw.2011.13189. eCollection 2011.

Abstract

The new paradigm of therapy in rheumatoid arthritis is to aim toward early and complete remission, using a larger use of conventional DMARDs and biologic agents. The present recommendations were established through a consensus to help practitioners in their daily use of those agents, to reflect the current "best practice" in Switzerland.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Biological Products / therapeutic use*
  • Humans
  • Methotrexate / therapeutic use
  • Remission Induction
  • Switzerland
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antirheumatic Agents
  • Biological Products
  • Tumor Necrosis Factor-alpha
  • Methotrexate